Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

MLA

Salhotra, Amandeep, et al. “Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.” Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 25, no. 2, Feb. 2019, pp. 287–92. EBSCOhost, https://doi.org/10.1016/j.bbmt.2018.09.009.

APA

Salhotra, A., Mei, M., Stiller, T., Mokhtari, S., Herrera, A. F., Chen, R., Popplewell, L., Zain, J., Ali, H., Sandhu, K., Budde, E., Nademanee, A., Forman, S. J., & Nakamura, R. (2019). Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 25(2), 287–292. https://doi.org/10.1016/j.bbmt.2018.09.009

Chicago

Salhotra, Amandeep, Matthew Mei, Tracey Stiller, Sally Mokhtari, Alex F Herrera, Robert Chen, Leslie Popplewell, et al. 2019. “Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.” Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 25 (2): 287–92. doi:10.1016/j.bbmt.2018.09.009.